Trumprx adds Amgen and GSK, widening discounts while the drug industry warns of long-term fallout

A government discount portal is moving from promise to pressure: trumprx is set to add two major drugmakers—Amgen and GSK—while the White House frames the effort as the start of a broader affordability drive and industry leaders caution that “most-favored-nation” pricing could carry consequences beyond the pharmacy counter.

What changed on Trumprx—and how big is the expansion?

The White House is expecting to announce an expansion of drugmakers offering discounts on a government website tied to the Trump administration’s drug-pricing push. As early as today (ET), Amgen and GSK are expected to be added to the list of prescription drug manufacturers offering discounts on the site.

The addition of Amgen and GSK would bring the total to 54 prescription medications from six pharmaceutical companies that have signed on to “most-favored-nation” pricing. The expansion is described as occurring under pressure from President Donald Trump and the threat of tariffs.

At a White House event on drug pricing on Feb. 5, 2026 (ET), President Donald Trump appeared with Centers for Medicare & Medicaid Services Administrator Mehmet Oz, underscoring that this effort is being treated as a central policy message, not a quiet pilot program.

Which medicines are being discounted, and what do the numbers show?

The newly listed discounts are described in specific, product-by-product terms—an unusual degree of granularity for a policy initiative that, in other contexts, often stays at the slogan level.

Amgen is expected to offer Amjevita with an 80% reduction from the retail price. Amjevita is described as having an original price of $1, 484 and a trumprx. gov price of $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.

Amgen also plans to list Aimovig and Repatha at discounts of 62%. On the GSK side, Incruse is expected to be discounted at 55% of the retail price and listed at $159; it is described as treating COPD. GSK also plans to list Arnuity, Relenza and Anoro with discounts ranging from 10% to 51%.

These announced reductions point to a strategy built around visible, easy-to-compare price cuts on a government site. The White House spokesman Kush Desai characterized the move as “another milestone” in what he called President Trump’s affordability push, while also signaling that the website is “just the beginning” and that “even greater drug pricing discounts, lower insurance premiums and more transparency” are expected if Congress passes President Trump’s Great Healthcare Plan.

What is not being told: who carries the costs, and what is Congress’ role?

Verified fact: The White House is presenting the portal and the “most-favored-nation” framework as a starting point, explicitly tying future discounts and insurance premium reductions to congressional action on President Trump’s Great Healthcare Plan. That linkage creates a central unanswered question for the public: which specific reforms are being sought in Congress, and how would they translate into lower premiums and “more transparency” in practice?

Verified fact: The Pharmaceutical Research and Manufacturers of America, the industry group representing major drug companies, is already pushing back on the policy premise. Its CEO, Stephen Ubl, warned that “Government-imposed most-favored-nation policies would undermine U. S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients. ” He also argued the policies would “siphon billions from American R& D, slow the pace of cures and increase reliance on China for future innovation. ”

Informed analysis (clearly labeled): The conflict on display is less about whether discounts are popular—they almost certainly are—than about who gets to define the true driver of high costs. The White House is emphasizing direct-to-consumer discounts and a pricing benchmark, while the industry’s institutional response pivots toward insurance practices and innovation funding. Those frames can both be politically useful: one delivers immediate, legible price cuts; the other warns of deferred costs that are harder for patients to observe at checkout.

Informed analysis (clearly labeled): The most important missing piece for public accountability is the enforcement and durability of the discounts on trumprx: how long the listed prices last, whether they can change without notice, and how the “threat of tariffs” interacts with voluntary participation by manufacturers. The White House describes a growing list and a milestone; the industry describes structural risk. Without the congressional details of the Great Healthcare Plan, the public is left to weigh two competing narratives with limited visibility into what comes next.

Who benefits, who is implicated, and what must be disclosed next?

The immediate beneficiaries are consumers who can access discounted medicines placed on the government website, including products such as Amjevita, Incruse, and other named medicines. The implicated parties are also clear: the White House, which is positioning the program as an affordability centerpiece; participating manufacturers, which are agreeing to discounts under stated pressure and tariff threats; and the industry trade group, which is warning of broader harms from a “government-imposed” approach.

There is also a political backdrop of bipartisan interest in drug pricing changes, as Democrats and Republicans look for common ground on fixes. But the operational future of the initiative, by the White House’s own framing, depends on Congress passing President Trump’s Great Healthcare Plan—placing lawmakers at the center of what discounts, premium impacts, and transparency requirements can be sustained over time.

Accountability now requires a basic standard of disclosure: the White House should publish the full list of the 54 medicines and the six participating companies, along with the rules governing price updates, the definition and application of “most-favored-nation” pricing, and a clear outline of the legislative components it wants Congress to enact. Absent that, trumprx risks becoming a policy symbol that the public can see—but not fully audit.